Incidence of EGFR Exon 19 deletions and 1858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2066-2070

  D'Angelo, Sandra P ^a   Pietanza, M Catherine ^a   Johnson, Melissa L ^a   Riely, Gregory J ^a   Miller, Vincent A ^a   Sima, Camelia S ^a   Zakowski, Maureen F ^a   Rusch, Valerie W ^a   Ladanyi, Marc ^a   Kris, Mark G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER STAGING; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL FEATURE; EXON; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX;

ADENOCARCINOMA; EXONS; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SMOKING;

EID: 79957510807     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.6181     Document Type: Article

References (19)

1. Li AR, Chitale D, Riely GJ, et al: EGFR mutations in lung adenocarcinomas: Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10:242-248, 2008 (Pubitemid 351692167)
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
4. Pao W, Kris MG, Iafrate AJ, et al: Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 15:5317-5322, 2009
5. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
6. National Comprehensive Cancer Network: NCCN Guidelines: Non-Small Cell Lung Cancer, Version 2.2011. Fort Washington, PA, National Comprehensive Cancer Network, 2011
7. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
8. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
9. Zhou C, Wu Y-L, Chen G, et al: Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small cell lung cancer patients. Ann Oncol 21:6, 2010 (suppl; abstr LBA13)
10. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
11. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700-1704, 2006 (Pubitemid 46622141)
12. Pan Q, Pao W, Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7:396-403, 2005 (Pubitemid 41149655)
13. Janjigian YY, McDonnell K, Kris MG, et al: Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 116:670-675, 2010
14. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844, 2006 (Pubitemid 43259866)
15. Janne PA, Wang XF, Socinski MA, et al: Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 28:539s, 2010 (suppl; abstr 7503)
16. Kris MG, Pao W, Zakowski M, et al: Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. J Clin Oncol 24:369s, 2006 (suppl; abstr 7021)
17. Brevet M, Arcila M, Ladanyi M: Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12:169-176, 2010
18. Kawahara A, Yamamoto C, Nakashima K, et al: Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16:3163-3170, 2010
19. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lungcancer cells. N Engl J Med 359:366-377, 2008